SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001347178-20-000009
Filing Date
2020-04-22
Accepted
2020-04-22 16:05:30
Documents
6
Period of Report
2019-12-31
Effectiveness Date
2020-04-22

Document Format Files

Seq Description Document Type Size
1 DEF 14A vnda-20200423xdef14a.htm DEF 14A 1791935
2 ceo2019piechart.jpg GRAPHIC 130885
3 neo2019piechart.jpg GRAPHIC 131339
4 proxycard2020page1.jpg GRAPHIC 241288
5 proxycard2020page2.jpg GRAPHIC 271407
6 proxyimage1a01.jpg GRAPHIC 24955
  Complete submission text file 0001347178-20-000009.txt   2889362
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-34186 | Film No.: 20808013
SIC: 2834 Pharmaceutical Preparations